# Challenges in funding of HIV/hep/TB response in Central and Eastern Europe:

## the role of EC and civil society in ensuring the sustainability of services



#### **Overall harm reduction funding in LMICs has flat-lined**

- Overall level of harm reduction funding in LMICs is the same as in 2007
- Just 1% of US\$19 billion donor and government spend on HIV in
- Just 4 cents per day is spent per person who inject drugs in LMICs
- Most funding for harm reduction still comes from international donors (64%), however it is one-quarter less than it was a decade ago
- National governments are not stepping in to scale up funding for


www.hri.global





The majority of people who inject drugs live in upper middle-income countries

#### 55% in UMICs



## Yet, harm reduction funding is lowest in these countries

**\$0.09** per person per day in low and lower middleincome countries

**\$0.02** per person per day in UMICs



www.hri.global

## People who use drugs are being left behind



New HIV infections among people who inject drugs increased 33% from 2011-15



www.hri.global

# EECA – lost in transition



#### TRANSITIONING


- If the country is ready for transition from donor's support to national funding of HIV\TB responses. Without proper planning, having all systems and legislation in place properly working, countries are not ready.
- If country is willing to ensure the transition of some particular components of HIV\TB responses previously supported by donors?
- If country is able to ensure the transition processes multiple factors could determine a country's ability to mobilize resources for HIV response

#### The Global Fund Sustainability, Transition and Co-financing Policy, 2016

Key resources on Sustainability and Transitioning in EECA countries



## GF updated allocation methodology for 2020-2022



## **Overview of EECA Transition**

#### **Status**

Ineligible before the policy on transition funding was adopted *	Receiving transition funding in 2017–2019	Projected to transition by 2025	Started transition planning (UMICs with high disease burden)	Still have time for long-term sustainability and transition planning (but most of these countries already started transition processes)
Bulgaria HIV B&H HIV, TB Macedonia HIV, TB Russia HIV Serbia TB	Albania HIV, TB Turkmenistan TB	Armenia HIV, TB Kosovo HIV, TB Kazakhstan HIV, TB	TB Belarus HIV, TB Georgia HIV, TB Montenegro	Kyrgyzstan HIV, TB Moldova HIV, TB Tajikistan HIV, TB Uzbekistan HIV, TB Ukraine HIV, TB

https://www.theglobalfund.org/media/4227/bm35\_06-eligibility\_policy\_en.pdf

#### **Different Europes**

- Challenges in services funding in EU members states: Romania, Bulgaria, Lithuania, Latvia...
- Need to develop mechanisms for transitioning in enlargement countries - Albania, Bosnia-Herzegovina, Kosovo, Macedonia, Montenegro, Serbia and Turkey
- 3. Support needed to neighboring countries: Armenia, Azerbaijan, Belarus, Georgia, Republic of Moldova, Morocco, Ukraine
- 4. Elephant in the room: Russia

#### Civil society forum on drugs report

- Expert group of the European Commission
- Report on the implementation of the EU Action Plan on Drugs from civil society perspective
- 169 CSOs filled it from 32 European countries (all member states except Malta)
- Respondents rated access to and quality of 12 services (including: OST, NSP, DCR, Naloxone, drug checking) in a 10 point scale




Figure 21. Perceived access to opiate substitution programs




Figure 19. Perceived access to needle and syringe programs


### Good students – bad students

- Income level is not the key factor but:
  - Sociocultural attitudes/civil society
  - Political system/leadership
  - Drug market changes
  - Funding environment
- The policies of individual governments are the key in how they use EU resources in advancing their health and social care systems
- We find both good and bad examples
  - <u>Good</u>: Czech Republic, Slovenia, Croatia
  - <u>Bad</u>: Bulgaria, Hungary, Romania






#### "GOOD STUDENTS" of HARM reduction




### "bad students" of harm reduction




"Happy families are all alike; every unhappy family is unhappy in its own way."

Lev Tolstoy



### Case study 1: Hungary


- 2000s: harm reduction is recognized and scaled up– national funding system developed
- 2010: new populist government
- Drug market is shifting to NPS stimulants
- 2014: largest NSPs are closed down in the country
- Hepatitis C outbreak among PWIDs



### Case study II: Romania


- 2010: financial crisis + end of support of international donors
- Shift in the drug market: rising injecting use of NPS
- Significant drop in distributed needles resulted in a huge HIV outbreak
- Funding is still not stable: the number of clients reached by NSPs declined from 7500 to 2000 between 2017 and 2018
- Drug policy is lost between ministries, Strategic Plan on HIV has been postponed for a year






### Case study III. Bulgaria







- With the help of Global Fund, Bulgaria built up a harm reduction system in the 2000s
- After 2017, the GF funding ended the government promised to create stable funding for HR programs
- Funding exists on paper but the requirements are so strict that no NGOs can apply for grants
- In 2018, NSP services left without funding, very limited service on voluntary base
- 2019: Bulgaria becomes eligible for GF again


## Components of the sevices sustainability

- Budget advocacy/availability and proper using of funds
- Mechanisms of funding of services (including provided by NGO)
- Standards of services/ Monitoring of services quality










### Do we have good arguments?


- 1. Access to HIV services for key populations is their basic human right (right for health)
- 2. Support of HIV prevention services for KAPs is state obligation based on the commitments to citizens\to donors
- 3. We already calculated all unit costs and estimated existing gaps in UHC and integrated health
- 4. State will benefit in long-term perspective if supports prevention now instead of paying for the treatment later
- 5. HIV prevention services for key populations successfully work in other countries and are being supported by high ranking officials (EC, GF, UN)

## Who is interested in sustainability of HIV/TB and HCV services for vulnerable groups?

#### **CRIMINALIZATION COSTS MAP** in Central and Eastern Europe and Central Asia (CEECA)



#### CRIMINALIZATION/FREEDOM COSTS COMPARISON



### Lithuania: waisted lives and 25 mln Euro

Because of recent criminalization of drug possession in Lithuania, registered crimes of the possession of drugs raised in 2018 by 17,7% (even till sept):

- In 2017 m. 1959
- In 2018 m. (January September) 2305

In 2017, **755** people were in prison for the drug possession in Lithuanian prisons. Average sentence for such crime, given by the court is 8 years and the real sentence is **4 years**. One day costs 23,31 Eur./ per day/ per prisoner so for one year it's **8508 Eur**. Investigation and court expenditures are not included, as well as lost incomes and taxes for this period.

Calculation: 755 people\*8508 Eur. (prison costs)\*4 years = 25 694 160,00 Euro

We'll see if this argument against criminalization of drugs possession will work during Lithuanian Parliament discussion next week.



#### Eastern Europe and Central Asia (EECA) communities campaign to stop stigma and discrimination

chasevirus.org

# CSF advocacy for services in EU members

- Prioritizing health in Euro Parliament and work of Commission
- Country by country targeted advocacy
- Using EU action plan on drugs and other obligations as bases

Recent example: <u>Senior-Level Policy Dialogue</u> <u>'Addressing HIV and TB Challenges</u>: from Donor Support to Sustainable Health Systems' which took place 12-13 December 2017 in Tallinn under the Estonian Presidency of the Council of the European Union

## Access to services in **enlargement** negotiations

- Country Strategy Papers influencing
- Participation or feed-back on annual Country Reports
- Instrument for Pre-accession Assistance (IPA) to support reforms in the enlargement countries with financial and technical help and other available technical support
- Additional bridging funding from GF, EJAF, OSF for advocacy and services institutionalization
- Bilateral donors: Norway, Sweden, Netherlands

#### The Sustainability Bridge Fund

#### (Civil Society Sustainability Network in partnership with Open Society Foundations)

#### Supporting advocacy to:

- Improve quality of policies that can increase cost and allocative effectiveness, such as procurement and supply policies, treatment normative guidance, prevention standards, etc
- Establish better national policies to engage with NGOs as service providers (social contracting)
- Inclusive national platforms to govern disease responses or broader health governance
- Ensuring better implementation of **transition workplans** such as:
  - Supporting dialogue between parliamentarians, civil society, academics and other critical in-country stakeholders
  - Supporting transition monitoring, oversight and broader efforts aimed at strengthening government accountability
- Piloting and championing **alternative domestic fundraising initiatives**, such as facilitating public-private partnerships, innovative financing, etc.
- Emergency funds to address critical service gaps and/or support for reestablishment of services where they have collapsed to demonstrate what must eventually be supported domestically.